Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

Muhammad Abdul-Ghani Eleuterio FerranniniGuntram SchernthanerStefan HantelUlrich ElsasserChristopher LeeThomas HachSøren S Lund

Published in: Endocrinology, diabetes & metabolism (2018)

Incremental reductions in HbA1c with increasing baseline HbA1c are greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

Keyphrases